SODIUM IODIDE I 123 by GE HealthCare is clinical pharmacology sodium iodide i-123 is readily absorbed from the upper gastrointestinal tract. First approved in 1976.
Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
Sodium Iodide I-123 is an oral radioactive diagnostic agent used for thyroid imaging and functional assessment. It is absorbed from the gastrointestinal tract, concentrated by the thyroid gland, and provides anatomical and functional information about thyroid tissue. The iodide is trapped and organically bound by thyroid cells, allowing visualization of normal and abnormal thyroid function.
Product approaching loss of exclusivity with moderate competitive pressure (30/100) and minimal linked job activity indicates a mature, smaller commercial footprint likely managed by a lean team.
CLINICAL PHARMACOLOGY Sodium iodide I-123 is readily absorbed from the upper gastrointestinal tract. Following absorption, the iodide is distributed primarily within the extracellular fluid of the body. It is trapped and organically bound by the thyroid and concentrated by the stomach, choroid…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on Sodium Iodide I-123 offers limited high-growth career opportunity, as the product is in late-stage maturity approaching loss of exclusivity. Roles focus on defending market share, regulatory compliance, and operational efficiency rather than launch momentum or pipeline expansion.
Worked on SODIUM IODIDE I 123 at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.